Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a report published on Saturday,Wall Street Zen reports.

A number of other analysts have also recently weighed in on TVRD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Wednesday, July 8th. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. Lucid Cap Mkts raised Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Finally, HC Wainwright started coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Tvardi Therapeutics Trading Up 4.7%

TVRD stock opened at $1.33 on Friday. The company has a market capitalization of $17.74 million, a P/E ratio of -0.48 and a beta of 0.32. Tvardi Therapeutics has a twelve month low of $0.93 and a twelve month high of $43.65. The business has a 50 day simple moving average of $1.89 and a 200-day simple moving average of $2.72.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Research analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new stake in Tvardi Therapeutics in the 2nd quarter valued at approximately $34,000. Susquehanna International Group LLP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $63,000. Finally, BlackRock Inc. purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.